During the past decade, Laureate Clinical Research Group conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 9 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 5 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Laureate Clinical Research Group" are "Osteoarthritis" (5 trials), "Arthritis" (3 trials), "Type 2 Diabetes" (2 trials), "Diabetes Type 2" (1 trials) and "Diabetes, Type I" (1 trials). Many other conditions were trialed in "Laureate Clinical Research Group" in a lesser frequency.

Most popular intervention types in "Laureate Clinical Research Group" are "Drug" (8 trials), "Biological" (5 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "tanezumab" (4 trials), "Placebo" (2 trials), "Technosphere Insulin Inhalation Powder" (2 trials), "Technosphere® Insulin Inhalation Powder" (2 trials) and "70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Laureate Clinical Research Group" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Laureate Clinical Research Group". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Laureate Clinical Research Group, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Laureate Clinical Research Group, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".